Please assess the completion status of the following clinical trial:

Trial Title: Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Untreated multiple myeloma requiring treatment~* Total cumulative dose of prior doxorubicin can not exceed 240 mg/m2~* Must have measurable disease~* Left Ventricular Ejection Fraction (LVEF) \>= 50 % determined by Multiple Gated Acquisition Scan (MUGA)~* Karnofsky performance status of \>= 60%~* Adequate bone marrow, liver and renal function~* Disease-free from prior malignancies \>= 5 years with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix~* Female participants (if of child bearing potential and sexually active) and male participants (if sexually active with a partner of child-bearing potential) must use medically acceptable methods of birth control.~Exclusion Criteria:~* Life expectancy of \>= 3 months~* Pregnant or breast feeding~* History of cardiac disease, with New York Heart Association Class II or greater, with congestive heart failure~* or unstable angina, uncontrolled hypertension or cardiac arrythmias or myocardial infarction within the last 6 months~* Uncontrolled diabetes mellitus or systemic infection~* Nonsecretory myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS) or smoldering myeloma~* Confusion, disorientation, or history of psychiatric illness which may impair patient's ability to give informed consent~* Prior chemotherapy to treat Multiple Myeloma~* Prior radiotherapy to an area greater than 1/3 of the skeleton~* Prior local radiotherapy within 1 week of treatment~* Any investigational agent within 30 days of the first dose of treatment~* Prior single agent dexamethasone (or another corticosteroid) to treat Multiple Myeloma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).